Trials / Completed
CompletedNCT04647487
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3484356 | Administered orally. |
Timeline
- Start date
- 2021-04-21
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
- First posted
- 2020-12-01
- Last updated
- 2025-11-12
- Results posted
- 2025-11-12
Locations
19 sites across 6 countries: United States, Belgium, France, Germany, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04647487. Inclusion in this directory is not an endorsement.